Miller Fisher Syndrome Associated With Immunotherapy for Metastatic Melanoma.

Baird-Gunning, Jonathan J D; Weerasinghe, Dinushi; Silsby, Matthew; Gawarikar, Yash; Carlino, Matteo S; Smith, Jessica L; Vucic, Steve

Baird-Gunning, Jonathan J D; Weerasinghe, Dinushi; Silsby, Matthew; Gawarikar, Yash; Carlino, Matteo S; Smith, Jessica L; Vucic, Steve.

Afiliação

Baird-Gunning JJD; Department of Neurology, Canberra Hospital, Garran, Australian Capital Territory, Australia.
Weerasinghe D; Department of Neurology, Westmead Hospital, Sydney, New South Wales, Australia.
Silsby M; Department of Neurology, Westmead Hospital, Sydney, New South Wales, Australia.
Gawarikar Y; Stroke Service, Calvary Public Hospital, Bruce, Australian Capital Territory, Australia.
Carlino MS; Department of Medical Oncology, Westmead and Blacktown Hospitals, the Melanoma Institute Australia and the University of Sydney, Australia.
Smith JL; Department of Medical Oncology, Westmead and Blacktown Hospitals, the Melanoma Institute Australia and the University of Sydney, Australia.
Vucic S; Department of Neurology, Westmead Hospital, Sydney, New South Wales, Australia.

Neurohospitalist ; 8(4): 191-193, 2018 Oct.

Article em En | MEDLINE | ID: mdl-30245770

Palavras-chave

CTLA-4 receptor; Miller-Fisher syndrome; PD-1 receptor; immunotherapy; melanoma

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Neurohospitalist Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google